This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Add The Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Beat the Market Like Zacks: Sprouts Farmers Market, Kroger, Masimo in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
BAX Stock Falls Despite Q3 Earnings & Sales Beat, Margins Decline
by Zacks Equity Research
Baxter reports better-than-expected third-quarter results. However, the company's gross and operating margins contract. Shares fall.
SOLV Stock Gains as Q3 Earnings & Sales Beat Estimates, '24 View Up
by Zacks Equity Research
Solventum's top line reflects the favorable impact of pricing normalization. Organic growth is primarily driven by rising demand for MedSurg products. The higher EPS outlook looks promising.
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
by Zacks Equity Research
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
by Zacks Equity Research
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks
by Zacks Equity Research
ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.
MASI Stock Gains Following Q3 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
Masimo's third-quarter 2024 results continue to benefit from the strength in its Healthcare business.
Masimo (MASI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Masimo (MASI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 16.67% and 0.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell or Hold DENTSPLY SIRONA Before Q3 Earnings?
by Zacks Equity Research
XRAY's third-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Should You Buy, Sell or Hold McKesson Before Q2 Earnings?
by Zacks Equity Research
MCK's second-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Cencora to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?
by Zacks Equity Research
Continued solid uptake of BD's products is expected to have driven fiscal fourth-quarter revenues.
Exploring Analyst Estimates for Masimo (MASI) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Masimo (MASI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Revvity to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China.
Will a Strong Evernorth Unit Benefit Cigna in Q3 Earnings?
by Zacks Equity Research
CI's Q3 results are likely to be aided by strength in the specialty pharmacy business, partly offset by elevated medical costs resulting from higher utilization trends.
Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Will Higher Expense Level Be a Woe for Humana in Q3 Earnings?
by Zacks Equity Research
HUM's Q3 results are likely to suffer from decline in commercial fully-insured premiums and higher operating costs, partly offset by a well-performing Medicare business.
Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lower Volume Likely to Hurt GE HealthCare's Q3 Earnings
by Zacks Equity Research
GEHC's third-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line figure may reflect better pricing.
Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down
by Zacks Equity Research
Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strong Segmental Performance to Drive Stryker's Q3 Earnings
by Zacks Equity Research
SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.